What DMT Is
N,N-Dimethyltryptamine (DMT) is a tryptamine alkaloid produced by hundreds of plant species across dozens of botanical families, as well as by marine organisms and certain invertebrates. It is also synthesised endogenously in humans and other mammals — detectable in blood, urine, and cerebrospinal fluid — though the physiological significance of endogenous DMT remains a subject of active investigation. Its biosynthesis in plants typically occurs as a chemical defence metabolite, though its functional roles vary across species and ecological contexts.
DMT is the primary psychoactive component of ayahuasca when combined with MAOI-containing plants, but the two contexts — inhaled/vaporised DMT and oral DMT in ayahuasca — produce experiences so different in duration, intensity, and phenomenological character that they are effectively distinct practices requiring separate consideration. This page addresses inhaled and vaporised N,N-DMT; see the Ayahuasca page for oral DMT in ceremonial context.
DMT should not be confused with 5-MeO-DMT — a structurally related but pharmacologically and phenomenologically distinct compound found in the Sonoran Desert toad and several plant species. The two compounds share a name suffix and a tryptamine skeleton but produce profoundly different experiences. See the 5-MeO-DMT page for that compound.
DMT is typically encountered as a white to yellow crystalline or waxy solid extracted from plant material (most commonly Mimosa hostilis root bark, Acacia confusa, or Psychotria viridis leaves). Extraction chemistry is widely documented in harm reduction literature. Purity and form vary; “freebase” DMT is the form most readily vaporised, while DMT fumarate and other salts are less volatile and require higher temperatures or alternative administration routes.
History & Cultural Roots
Indigenous peoples across the Amazon basin, the Caribbean, and parts of South America have used DMT-containing plant preparations for ceremonial, healing, and divinatory purposes for thousands of years. Archaeological evidence for snuffed plant preparations containing DMT (and 5-MeO-DMT) dates to at least 3000 BCE in the Atacama Desert of northern Chile. In the Caribbean and parts of South America, cohoba snuff — prepared from Anadenanthera peregrina seeds, which contain DMT alongside bufotenine — was central to Taíno and Arawakan ceremonial practices documented by early European colonisers.
In the Amazon, DMT-containing plants (Psychotria viridis, Diplopterys cabrerana) function primarily as admixtures to ayahuasca rather than being used in isolation. Smoked DMT as a standalone practice is largely a Western innovation: Richard Evans Schultes documented DMT in Piptadenia peregrina in the 1940s, and the synthesis of DMT was accomplished by Manske in 1931. Its psychoactivity was discovered independently by Stephen Szára in 1956. William Burroughs, Terence McKenna, and the counterculture catalysed its spread in Western subcultures from the 1960s onward. McKenna’s descriptions — popularised through his lectures and writings — established much of the cultural mythology around DMT: machine elves, hyperspace, the “spirit molecule.” Rick Strassman’s clinical research at the University of New Mexico in the early 1990s was the first human trials of DMT in the United States, producing findings (and a popular book) that significantly shaped subsequent Western perception of the compound.
How DMT Works
Receptor pharmacology
DMT acts primarily as an agonist at 5-HT2A receptors — the same primary receptor target as psilocin, LSD, and mescaline — producing the characteristic features of classic psychedelic experience. It also shows significant activity at 5-HT2C receptors, sigma-1 receptors (thought to contribute to its unusual experiential quality and possibly its neuroprotective effects), trace amine-associated receptors (TAARs), and various other receptor subtypes. Its interaction with sigma-1 receptors, in particular, has generated scientific interest: sigma-1 receptors modulate neuroinflammation, neural plasticity, and cellular stress responses, and some researchers propose that this mechanism may contribute to both DMT’s distinctive phenomenology and potential therapeutic effects.
When inhaled, DMT produces peak plasma concentrations within 2–3 minutes and is rapidly metabolised by monoamine oxidase (MAO) enzymes — particularly MAO-A — both peripherally and in the brain. This rapid metabolism is responsible for the characteristically short duration of smoked DMT. When MAO is inhibited (as in ayahuasca, where MAOI-containing plants are combined with DMT-containing plants), oral DMT becomes active and the experience extends to 4–6 hours. Without MAO inhibition, orally consumed DMT is almost entirely metabolised before reaching the brain and produces no psychoactive effect.
Endogenous DMT
The detection of DMT in mammalian tissue — including human blood, urine, and the pineal gland — has fuelled longstanding speculation about endogenous roles: theories about DMT and near-death experiences, dreaming, or mystical states. The “spirit molecule” hypothesis proposed by Rick Strassman suggests endogenous DMT may play a role in extraordinary states of consciousness. This remains speculative: the concentrations at which endogenous DMT is detected are orders of magnitude below those required for psychoactive effects under normal conditions, and its endogenous function is not established. The sigma-1 receptor may be the more relevant target for endogenous DMT at physiological concentrations.
Effects
Onset and intensity
Inhaled DMT is among the fastest-acting psychoactive compounds known. Effects begin within seconds of inhalation, reach full intensity within 2–5 minutes, and return to baseline within 15–30 minutes in most cases. The rapidity and intensity of onset is one of DMT’s most distinctive — and, for some people, most challenging — features. There is typically very little transitional space between sober consciousness and the peak experience; the compound takes hold before most people have time to orient to what is happening.
The experiential character of a significant DMT dose is unlike any other commonly used psychedelic. Common reports include a complete dissolution of ordinary physical and temporal reality; immersion in a highly structured alternate space, often described as more real than ordinary consciousness; encounters with autonomous entities — described variously as machine elves, teachers, interdimensional beings, or presences of profound otherness — that communicate, often without language; geometric and architectural visuals of extraordinary complexity and apparent purpose; and a sense of noetic certainty (the felt conviction that one is perceiving something real and important) that can be disorienting to integrate afterward.
Entity encounters
Entity encounters are reported by a large proportion of DMT users in survey research and are among the most discussed and debated phenomena in psychedelic science. Timmermann and colleagues (2019) found that 58% of participants in a survey study reported encountering entities, and that most described the experience as the most meaningful of their lives. The ontological status of these entities — whether they represent aspects of the individual’s unconscious, products of neurological reorganisation, or something else — is genuinely contested and not resolved by current science. Committed positions in either direction (they are “just” neural artefacts, or they are objectively real) outrun the evidence. The phenomenological reality of these encounters — their experienced vividness and significance — is not in doubt.
Duration note
Standard smoked DMT experience: 15–30 minutes to baseline. Extended-state DMT (ESDMT) protocols — delivering DMT via intravenous infusion at sub-breakthrough doses for extended periods — have been investigated by Timmermann and colleagues at Imperial College London and produce sustained altered states lasting up to several hours, allowing more structured observation and therapeutic use. Oral DMT with MAOI (ayahuasca): 4–6 hours.
Dosage & Routes
These ranges apply to smoked/vaporised freebase DMT. Potency of extract varies; start lower than these ranges with unfamiliar material.
| Level | Smoked/Vaporised (freebase) | Character |
|---|---|---|
| Threshold | 5–15 mg | Mild visual effects, bodily warmth. Does not typically produce breakthrough. |
| Low | 15–25 mg | Significant perceptual change; immersive visuals. Reality remains partially present. |
| Breakthrough | 25–50+ mg | Complete replacement of ordinary reality. Entity encounters typical. Most reports involve 30–50 mg. |
Administration methods
DMT freebase has a low boiling point and degrades quickly at high temperatures — standard combustion pipes destroy most of the compound. Effective methods include: vaporisation using a purpose-designed vaporiser or a “machine” (glass bulb vaporiser); the “sandwich” method (sandwiching DMT between layers of inert herb in a pipe, avoiding direct flame contact); and infusion devices. Intravenous administration is used in clinical research settings. Snorting DMT salts (fumarate or hydrochloride) is painful and poorly absorbed but produces a slower, lower-intensity effect. Plugging (rectal administration) of DMT salts is also used in harm reduction contexts for more gradual onset.
Proper vaporisation technique is critical. Users who inhale at too low a temperature or too quickly may not achieve an effective dose and may waste significant material while exposing themselves to partial effects that produce anxiety without the full experiential context. The typical instruction is to inhale slowly, hold briefly, and aim for 2–3 inhalations to achieve a breakthrough dose — though technique varies by device.
What the Research Shows
DMT research has accelerated significantly in the past decade. Strassman’s foundational clinical work in the 1990s documented the phenomenological character of IV DMT administration systematically for the first time. Timmermann and colleagues at Imperial College London have led the most rigorous contemporary research: their work characterises the neural correlates of the DMT state using EEG and fMRI, documents entity encounter prevalence, explores the theta-burst EEG signature unique to DMT, and investigates DMT-induced neuroplasticity mechanisms. A clinical trial examining IV DMT for major depressive disorder is underway at Imperial, making DMT one of several psychedelics now in formal therapeutic investigation.
Survey research has established population-level patterns: Gallimore and Strassman (2016) proposed that DMT induces a “reality switch” — a functional replacement of ordinary perceptual reality — rather than overlaying it, distinguishing it phenomenologically from other psychedelics. Entity encounter surveys (Davis et al., 2020; Timmermann et al., 2019) establish prevalence rates and find that most experiencers rate entities as conscious, benevolent, and as sources of insights or information. The meaning-making dimensions of DMT are substantial and require integration frameworks that can hold material of unusual experiential intensity.
Risks & Contraindications
DMT in ayahuasca form is combined with MAOIs by design — but combining smoked DMT with pharmaceutical MAOIs or SSRIs carries serious interaction risks. View full drug interaction chart →
DMT’s short duration contributes to a relatively contained safety profile — the window of incapacitation is brief, and physiological effects (mild increases in blood pressure and heart rate) are transient. There are no documented deaths from DMT toxicity alone at commonly used doses. The primary risks are:
Psychological overwhelm: The rapidity and totality of DMT’s onset leaves no transition time. People who are psychologically unprepared for complete ego dissolution and reality replacement may experience terror. Having a trusted sitter present is strongly recommended for any breakthrough dose.
Physical safety during the experience: During a breakthrough DMT experience, physical coordination is temporarily absent. Users must be seated or lying down in a safe environment; attempting to stand or move during peak effects carries a real fall risk.
Serotonin syndrome with MAOIs: Combining smoked DMT with MAO inhibitors — either pharmaceutical MAOIs or the MAOI-containing plants used in ayahuasca — is dangerous and can produce serotonin syndrome. Syrian rue (Peganum harmala) is sometimes smoked alongside DMT to extend its duration; this combination carries serotonin syndrome risk and must be approached with care. Pharmaceutical MAOIs are an absolute contraindication.
Cardiovascular: Blood pressure and heart rate increase transiently. Individuals with significant cardiac disease, hypertension, or risk factors should assess this carefully before use.
Personal or family history of psychosis: As with all classic psychedelics, this is a contraindication.
Integration challenges: The ontological disruption produced by a breakthrough DMT experience — particularly entity encounters — can be genuinely disorienting to integrate within ordinary frameworks of reality and meaning. Having access to integration support from someone familiar with non-ordinary states is valuable, particularly after intense experiences.
Legal Status
DMT is scheduled as a controlled substance in most jurisdictions globally, typically in the same class as psilocybin and LSD. In the United States it is Schedule I; in the UK, Class A; in Canada, Schedule III. Some countries’ scheduling of plant preparations containing DMT is distinct from scheduling the pure compound — legal nuances vary by jurisdiction. Ayahuasca’s legal status, being a plant preparation with cultural heritage dimensions, differs from that of extracted DMT in several countries. In Brazil, ayahuasca is legal for religious use, with downstream implications for its constituent compounds. In most jurisdictions, extracted DMT is illegal regardless of its plant origin.
Frequently Asked Questions
Yes — DMT has been detected in human blood, urine, and tissues, and the biosynthetic enzymes necessary to produce it are expressed in the brain, particularly in the choroid plexus and pineal gland. Whether endogenous DMT is produced in physiologically relevant concentrations, and whether it plays a functional role in normal consciousness, dreaming, or extraordinary states, remains genuinely uncertain. The concentrations detected are orders of magnitude below those required for psychoactive effects, and the “spirit molecule” hypothesis — that endogenous DMT mediates near-death experiences or mystical states — remains speculative. It is an interesting and open scientific question, not an established fact.
The honest answer is: we don’t know. The phenomenological reality of DMT entity encounters — their experienced vividness, apparent independence, and communicative quality — is not in doubt; this is what people consistently report. Whether these entities have any existence independent of the human nervous system generating the experience is a genuinely unresolved question that current science cannot answer. Dismissing them as “just” neural artefacts requires the same kind of ontological confidence as asserting they are independently real — and that confidence is not warranted by available evidence. Approaching them phenomenologically — taking the experience seriously as an experience without committing to strong metaphysical claims about its ultimate nature — is probably the most intellectually honest position available.
N,N-DMT and 5-MeO-DMT share a tryptamine backbone but differ in one methoxy group — and this chemical difference produces profoundly different experiences. N,N-DMT typically produces rich, structured visual content: complex geometric architecture, distinct spaces, entity encounters with specific character. 5-MeO-DMT produces an experience characterised by the complete dissolution of content into undifferentiated, boundless awareness — no visuals, no entities, just the obliteration of self and world into a formless field. Many people describe 5-MeO-DMT as the more overwhelming of the two, despite producing less visual content. They require entirely separate harm reduction consideration and should not be conflated. See the 5-MeO-DMT page.
Cannabis is sometimes used before or alongside DMT, and it intensifies the experience substantially for many people — accelerating onset-like anxiety, amplifying intensity, and affecting the quality of the visionary content. This combination is not recommended for inexperienced users and should be approached with considerable caution even for those with experience of both substances separately. Cannabis can tip a manageable DMT experience toward overwhelming difficulty. Starting with less of both and having a sober sitter present is essential if this combination is being attempted.
The brevity of smoked DMT is due to rapid breakdown by MAO enzymes in the body and brain. The experience is short by the same pharmacological logic that makes it active at all when inhaled — the same enzyme system that could destroy it if taken orally is also what limits its duration. The primary way to extend DMT experience is to inhibit MAO, as ayahuasca does with harmaline and harmine. Extended-state DMT (ESDMT) through IV infusion is the other approach, used in clinical research settings. Combining smoked DMT with MAO inhibitors is effective but carries serotonin syndrome risk and requires careful attention to dose and timing — this combination should not be attempted without thorough research and ideally experienced guidance.